Centessa Pharmaceuticals (NASDAQ:CNTA) Insider Karen Anderson Sells 64,768 Shares

Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) insider Karen Anderson sold 64,768 shares of the business’s stock in a transaction on Monday, March 16th. The shares were sold at an average price of $28.21, for a total transaction of $1,827,105.28. Following the sale, the insider owned 62,085 shares of the company’s stock, valued at approximately $1,751,417.85. This represents a 51.06% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link.

Centessa Pharmaceuticals Trading Down 0.8%

Shares of CNTA stock traded down $0.24 during mid-day trading on Wednesday, reaching $28.71. 1,835,638 shares of the company’s stock traded hands, compared to its average volume of 1,195,469. The company has a current ratio of 10.56, a quick ratio of 10.57 and a debt-to-equity ratio of 0.36. Centessa Pharmaceuticals PLC Sponsored ADR has a 12 month low of $9.60 and a 12 month high of $30.58. The firm has a 50 day moving average price of $24.92 and a two-hundred day moving average price of $24.51.

Analyst Ratings Changes

A number of brokerages recently commented on CNTA. TD Cowen reaffirmed a “buy” rating on shares of Centessa Pharmaceuticals in a report on Wednesday, January 14th. Chardan Capital reissued a “buy” rating and set a $30.00 target price on shares of Centessa Pharmaceuticals in a research note on Friday, January 2nd. Oppenheimer raised their price objective on Centessa Pharmaceuticals from $40.00 to $62.00 and gave the stock an “outperform” rating in a report on Wednesday, December 10th. Truist Financial boosted their price target on shares of Centessa Pharmaceuticals from $33.00 to $38.00 and gave the company a “buy” rating in a report on Thursday, January 29th. Finally, Guggenheim upped their price objective on Centessa Pharmaceuticals from $28.00 to $43.00 and gave the stock a “buy” rating in a research note on Tuesday, November 18th. Two equities research analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus price target of $39.80.

Institutional Trading of Centessa Pharmaceuticals

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Campbell & CO Investment Adviser LLC acquired a new stake in shares of Centessa Pharmaceuticals in the second quarter valued at about $218,000. American Century Companies Inc. boosted its holdings in Centessa Pharmaceuticals by 3.5% in the 2nd quarter. American Century Companies Inc. now owns 1,130,708 shares of the company’s stock valued at $14,858,000 after purchasing an additional 37,954 shares during the last quarter. Eagle Health Investments LP purchased a new stake in shares of Centessa Pharmaceuticals in the 3rd quarter valued at approximately $2,500,000. Federated Hermes Inc. acquired a new stake in shares of Centessa Pharmaceuticals during the 3rd quarter worth approximately $42,429,000. Finally, Royce & Associates LP purchased a new stake in shares of Centessa Pharmaceuticals during the 3rd quarter valued at approximately $5,999,000. Institutional investors and hedge funds own 82.01% of the company’s stock.

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc is a global clinical‐stage biopharmaceutical company focused on the discovery and development of innovative therapies across multiple disease areas. The company operates a modular R&D network, bringing together a portfolio of independent, specialist research entities under a single corporate umbrella. This structure is designed to accelerate decision‐making and resource allocation while leveraging deep scientific expertise in each therapeutic domain.

Centessa’s pipeline spans oncology, immunology, neuroscience, cardiovascular and metabolic diseases, as well as rare genetic disorders.